Catalyst Pharms Drug Patent Portfolio

Catalyst Pharms owns 3 orange book drugs protected by 14 US patents Given below is the list of Catalyst Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11382922 Aqueous oral pharmaceutical suspension compositions 16 Jul, 2040
Active
US11471471 Aqueous oral pharmaceutical suspension compositions 17 Mar, 2040
Active
US10626088 Determining degradation of 3,4-diaminopyridine 25 Feb, 2037
Active
US10793893 Methods of administering 3,4-diaminopyridine 26 May, 2034
Active
US11690853 Non-hormonal steroid modulators of NF-κβ for treatment of disease 07 Mar, 2033
Active
US11060128 Methods of administering 3,4-diaminopyridine 29 Jun, 2032
Active
US11268128 Methods of administering 3,4-diaminopyridine 29 Jun, 2032
Active
US11274331 Methods of administering 3,4-diaminopyridine 29 Jun, 2032
Active
US11274332 Methods of administering 3,4-diaminopyridine 29 Jun, 2032
Active
US10857161 Non-hormonal steroid modulators of NF-kB for treatment of disease 28 May, 2029
Active
US11833159 Non-hormonal steroid modulators of NF-kB for treatment of disease 28 May, 2029
Active
US8334279 Non-hormonal steroid modulators of NF-κB for treatment of disease 28 May, 2029
Active
US8772497 Method for producing 1, 2-dihydropyridine-2-one compound 01 Jul, 2026
Active
US6949571 1,2-dihydropyridine compounds, process for preparation of the same and use thereof 23 May, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Catalyst Pharms.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 10 Jun, 2024 US10857161
Payment of Maintenance Fee, 12th Yr, Small Entity 05 Jun, 2024 US8334279
Second letter to regulating agency to determine regulatory review period 15 May, 2024 US8334279
Second letter to regulating agency to determine regulatory review period 15 May, 2024 US10857161
Second letter to regulating agency to determine regulatory review period 15 May, 2024 US11690853
Letter from FDA or Dept of Agriculture re PTE application 08 May, 2024 US10857161
Letter from FDA or Dept of Agriculture re PTE application 08 May, 2024 US11690853
Letter from FDA or Dept of Agriculture re PTE application 08 May, 2024 US8334279
Payment of Maintenance Fee, 4th Year, Large Entity 31 Mar, 2024 US10793893
Patent Term Extension Certificate 11 Mar, 2024 US6949571
PTE Interim Patent Extension filed 29 Feb, 2024 US6949571
Surcharge for late Payment, Small Entity 04 Jan, 2024 US10626088
Payment of Maintenance Fee, 4th Yr, Small Entity 04 Jan, 2024 US10626088
Initial letter Re: PTE Application to regulating agency 22 Dec, 2023 US10857161
Initial letter Re: PTE Application to regulating agency 22 Dec, 2023 US8334279


Catalyst Pharms's Family Patents

Catalyst Pharms drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 20.4% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Catalyst Pharms Drug List

Given below is the complete list of Catalyst Pharms's drugs and the patents protecting them.


1. Agamree

Agamree is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11382922 Aqueous oral pharmaceutical suspension compositions 16 Jul, 2040
(15 years from now)
Active
US11471471 Aqueous oral pharmaceutical suspension compositions 17 Mar, 2040
(15 years from now)
Active
US11690853 Non-hormonal steroid modulators of NF-κβ for treatment of disease 07 Mar, 2033
(8 years from now)
Active
US10857161 Non-hormonal steroid modulators of NF-kB for treatment of disease 28 May, 2029
(4 years from now)
Active
US11833159 Non-hormonal steroid modulators of NF-kB for treatment of disease 28 May, 2029
(4 years from now)
Active
US8334279 Non-hormonal steroid modulators of NF-κB for treatment of disease 28 May, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Agamree's drug page


2. Firdapse

Firdapse is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10626088 Determining degradation of 3,4-diaminopyridine 25 Feb, 2037
(12 years from now)
Active
US10793893 Methods of administering 3,4-diaminopyridine 26 May, 2034
(9 years from now)
Active
US11060128 Methods of administering 3,4-diaminopyridine 29 Jun, 2032
(7 years from now)
Active
US11268128 Methods of administering 3,4-diaminopyridine 29 Jun, 2032
(7 years from now)
Active
US11274331 Methods of administering 3,4-diaminopyridine 29 Jun, 2032
(7 years from now)
Active
US11274332 Methods of administering 3,4-diaminopyridine 29 Jun, 2032
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firdapse's drug page


3. Fycompa

Fycompa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8772497 Method for producing 1, 2-dihydropyridine-2-one compound 01 Jul, 2026
(1 year, 8 months from now)
Active
US6949571 1,2-dihydropyridine compounds, process for preparation of the same and use thereof 23 May, 2025
(7 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fycompa's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List